We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Copper Complex Halts Botulinum Neurotoxin Poisoning

By HospiMedica International staff writers
Posted on 12 Jun 2017
A new study describes how a readily available metal salt could provide a new therapy for Botulinum Neurotoxin type A (BoNT/A), the most common and deadly cause of human botulism.

Researchers at the Scripps Research Institute (TSRI; La Jolla, CA, USA), Boston University (MA, USA), and other institutions conducted a study that screened various triazole compounds against the BoNT/A light chain (LC) protease, a proteolytic enzyme that disrupts neuronal signaling to muscles. More...
They found to their surprise that it was metal salts, and not the triazole compounds that showed marked inhibitory activity, and that copper cations in particular displayed noncompetitive inhibition of the LC, with mercury cations 10-fold more potent.

They then examined ligand-copper complexes in a cell-based model, and found that they too prevented BoNT/A cleavage of the endogenous protein substrate (SNAP-25) even at low μM concentrations. The researchers suggest that a bio-reductive mechanism caused an intracellular release of copper, which directly inhibited the BoNT/A protease. Further in-vivo experiments in rodents showed that copper (II) dithiocarbamate and bis(thiosemicarbazone) complexes could be used to treat the harmful effects of BoNT/A intoxication. The study was published on May 5, 2017, in JACS.

“Currently, botulism sufferers receive an anti-toxin medicine that can inactivate the toxin circulating in their system, thereby preventing further poisoning. However, the anti-toxin cannot reverse preexisting paralysis because the toxin acts inside cells,” said lead author Professor Kim Janda, PhD, of the TSRI department of chemistry. “Consequently, disease recovery can be slow, and paralysis may take weeks or months to wear off. This new therapy can readily enter cells where it can attack the etiological agent, a protease, which is responsible for paralysis seen from the neurotoxin.”

BoNT-A is probably best known as Botox, an injectable toxin commonly used to treat various movement disorders, such as focal dystonias, and in cosmetic treatments by paralyzing smooth muscles that cause wrinkles. It is also one of the most potent toxins on earth, and is classified as a potential bioterrorism threat, together with as Anthrax, Plague, Ebola, and other Category A priority pathogens.

Related Links:
Scripps Research Institute
Boston University

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: IMX742 CMOS image sensor for single-use endoscopes (Photo courtesy of Sony Semiconductor Solutions Corporation)

Miniature Image Sensor Enables Digital Imaging in Single-Use Endoscopes

Disposable single-use endoscopes are increasingly used to help reduce infection risk and the burden of post-procedure reprocessing and equipment management. As insertion sections become thinner, endoscopic... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.